Clinical Trial Update: Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing bicalutamide (Casodex) to placebo in patients with early prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide)

Snippet

Sponsor: AstraZeneca | Conditions: Non-metastatic Prostate Cancer | Phase 3 | Status: COMPLETED